PURPOSEThe use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This …
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…
The Food and Drug Administration granted accelerated approval to encorafenib.
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the…
According to data presented at the 66th ASH Annual Meeting, the addition of PXS-5505 to ruxolotinib therapy demonstrated safety and potential efficacy for patients with…
The Food and Drug Administration granted accelerated approval to encorafenib.
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…
